Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface?

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Systemic chemotherapy often causes significant morbidity due to non-specific side effects and drug toxicity.
• Advances in understanding gene expression and biochemical pathways enable targeted cancer therapies.

Discussion:

• This study explores a targeted chemotherapy approach for prostate cancer using prostate-specific membrane antigen (PSMA) and methotrexate conjugates.
• The enzymatic activity of PSMA was utilized to achieve selective drug delivery and toxicity.
• Substrate specificity and activity were assessed using soluble PSMA, and selective toxicity was evaluated in PSMA+ and PSMA- cancer cell lines.

Key Insights:

• Peptide conjugates of methotrexate demonstrated enhanced selective clonal inhibition in the presence of PSMA.
• This indicates a potential for PSMA-targeted drug delivery to improve efficacy and reduce toxicity in prostate cancer treatment.

Outlook:

• Further research is needed to address variables like substrate stability and non-PSMA dependent drug uptake for clinical feasibility.
• PSMA-targeted therapy holds promise but requires careful consideration before widespread clinical application.